Literature DB >> 1373372

Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin.

E Ben-Menachem1, L I Persson, T Hedner.   

Abstract

Gabapentin (GBP) is a neutral amino acid and a GABA analog which in animal experimental models has shown a broad anticonvulsant spectrum. To evaluate the penetration of GBP into the CSF in humans as well as its possible effects on free and total GABA, homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA), a special investigation was performed as part of a placebo controlled add-on study of GBP in partial epilepsy. At the end of the 3-month double-blind period, 5 patients on placebo were given a single oral dose of GBP. Four patients received 600 mg and 1 patient 1200 mg GBP. CSF was collected immediately before and at 6, 24 and 72 h after the single dose. 5 ml of plasma was collected at 1, 2, 3, 6, 12, 24, 48 and 72 h. Plasma concentrations and plasma elimination half-life (4-6 h) of GBP were in agreement with the results of previous studies. The CSF/plasma concentration ratio of GBP 6 h after drug was 0.1. After 24 h, GBP could only be recovered in the CSF of the patient given 1200 mg. The CSF/plasma ratio at that time was 0.3. Free and total GABA concentrations did not change, but CSF 5-HIAA and HVA increased at 24 and 72 h post dose. The CSF/plasma ratio of gabapentin is similar to that of other amino acids.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373372     DOI: 10.1016/0920-1211(92)90020-t

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  15 in total

Review 1.  Therapeutic drug monitoring--antiepileptic drugs.

Authors:  M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

2.  The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach.

Authors:  Y Wang; D F Welty
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

Review 3.  A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Authors:  Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

4.  Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels.

Authors:  Rían W Manville; Geoffrey W Abbott
Journal:  Mol Pharmacol       Date:  2018-07-18       Impact factor: 4.436

5.  Nerve injury-induced calcium channel alpha-2-delta-1 protein dysregulation leads to increased pre-synaptic excitatory input into deep dorsal horn neurons and neuropathic allodynia.

Authors:  C Zhou; Z D Luo
Journal:  Eur J Pain       Date:  2015-02-17       Impact factor: 3.931

Review 6.  The use of newer anticonvulsants in neuropsychiatric disorders.

Authors:  Edward Kim
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

Review 7.  Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy.

Authors:  Karen L Goa; Eugene M Sorkin
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 8.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 9.  Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine.

Authors:  R D Elwes; C D Binnie
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 10.  Gabapentin: in postherpetic neuralgia.

Authors:  Monique P Curran; Antona J Wagstaff
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.